NRXP
NRx Pharmaceuticals, Inc.
There isn't enough reported data to score NRXP yet.
NRXP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
NRXP's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
NRXP PE Valuation
NRXP has no meaningful PE right now: it lost money over the past year.
NRXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NRXP's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NRXP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$2.29 | -$0.12 |
| Q2 2025 | -$2.17 | +$0.55 |
| Q1 2025 | -$1.94 | +$1.23 |
| Q4 2024 | -$2.36 | +$1.67 |
| Q3 2024 | -$2.17 | +$2.83 |
| Q2 2024 | -$2.72 | +$2.98 |
| Q1 2024 | -$3.17 | +$2.43 |
| Q4 2023 | -$4.03 | +$1.97 |
NRXP is still losing money, but far less than before: $2.29 per share over the past year, against $19.00 at its worst in mid-2022.
NRXP Quarterly Revenue
NRXP's revenue has grown year over year every quarter since late 2025: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -591% | N/A |
| Q1 2026 | -444% | N/A |
| Q4 2025 | -470% | N/A |
| Q3 2025 | -1663% | N/A |
NRXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$815K |
| Q4 2025 | -$3.7M | -$1.6M |
| Q3 2025 | -$2.9M | -$585K |
| Q4 2024 | -$2.1M | +$1.1M |
| Q3 2024 | -$2.3M | +$2.3M |
| Q4 2023 | -$3.2M | +$5.1M |
| Q3 2023 | -$4.6M | +$1.7M |
| Q2 2023 | -$7.8M | +$7M |
NRXP has burned cash in almost every quarter: −$15M over the past year, against −$11M the year before.
NRXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +5.3M shares |
| 1 year | +118% | +20.4M shares |
| 3 years | +472% | +31.1M shares |
| 5 years | +13858% | +37.4M shares |
| Available history | +13340% | +37.4M shares |
NRXP has 38M diluted shares, up 118% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | $299,253 |
| Q2 2020 | — |
| Q1 2020 | $26M |
| Q3 2019 | $8.9M |
NRXP Net Leverage
NRXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NRXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 10.6 | Oversold |
NRXP's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
NRXP PE vs Healthcare Sector
| Metric | NRXP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRXP has no meaningful PE right now: it lost money over the past year.
NRXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.60 | 12% below |
| 20 week MA | $3.21 | 29% below |
| 50 week MA | $2.85 | 20% below |
| 100 week MA | $2.78 | 18% below |
| 200 week MA | $3.47 | 34% below |
NRXP is in a downtrend: it's below all five of its weekly moving averages, and 34% below its 200-week average.
NRXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.5 | $296.4 | +178% |
| 2021 | $296.4 | $50.4 | -83% |
| 2022 | $50.4 | $10.8 | -79% |
| 2023 | $10.8 | $4.60 | -57% |
| 2024 | $4.60 | $1.51 | -67% |
| 2025 | $1.51 | $2.56 | +70% |
| 2026 YTD | $2.56 | $2.28 | -11% |
NRXP's yearly returns have swung widely, from +178% in 2020 to −83% in 2021. It's down 11% so far in 2026.